Diabetes Drugs In DPP-4 Inhibitor Class Associated With Almost Two-Times Increased Risk of Cholangiocarcinoma

Medical Researchers Finding This Rare But Highly Fatal Cancer Call For More Investigation Into This Possible Drug Side Effect   (Posted by Tom Lamb at DrugInjuryWatch.com)   A recent medical study shows that the use of diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class was associated with a near doubling of the risk of cholangiocarcinoma. Diabetes drugs in the DPP-4 inhibitors class include the following: Januvia (sitagliptin) Janumet (sitagliptin / metformin HCl) Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin) Qtern (dapagliflozin and saxagliptin) Nesina (alogliptin) Kazano (alogliptin and metformin) Oseni (alogliptin and pioglitazone) Tradjenta (linagliptin) Jentadueto (linagliptin and metformin HCl) Glyxambi (empagliflozin / linagliptin) From this BMJ article, "Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study", published December 2018 we get…

Read more detail on Recent Injury and Accident Law posts –

This entry was posted in Injury & Accident Law and tagged , , , , , , , , , , . Bookmark the permalink.

Leave a Reply